Patten & Patten Inc. TN Buys 235 Shares of Moderna, Inc. (NASDAQ:MRNA)

Patten & Patten Inc. TN grew its stake in shares of Moderna, Inc. (NASDAQ:MRNAFree Report) by 2.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,823 shares of the company’s stock after purchasing an additional 235 shares during the period. Patten & Patten Inc. TN’s holdings in Moderna were worth $877,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of MRNA. First Pacific Financial bought a new stake in Moderna during the third quarter worth about $27,000. ICA Group Wealth Management LLC bought a new stake in Moderna during the fourth quarter worth about $27,000. Stonebridge Capital Advisors LLC boosted its stake in Moderna by 79.1% during the first quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock worth $49,000 after acquiring an additional 125 shares in the last quarter. Ancora Advisors LLC boosted its stake in Moderna by 41.2% during the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after acquiring an additional 96 shares in the last quarter. Finally, GPS Wealth Strategies Group LLC boosted its stake in Moderna by 54.1% during the third quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock worth $53,000 after acquiring an additional 180 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00. Following the completion of the transaction, the director now directly owns 2,101,931 shares in the company, valued at $229,236,594.86. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16. Following the sale, the president now owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the sale, the director now directly owns 2,101,931 shares in the company, valued at approximately $229,236,594.86. The disclosure for this sale can be found here. Insiders sold a total of 65,021 shares of company stock worth $6,847,342 over the last three months. 15.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Canaccord Genuity Group boosted their price objective on shares of Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research note on Friday, February 23rd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 target price on shares of Moderna in a report on Thursday, March 28th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Thursday, March 28th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Monday. Finally, HSBC reaffirmed a “reduce” rating and issued a $86.00 target price (up from $75.00) on shares of Moderna in a report on Monday, February 26th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $129.82.

Read Our Latest Research Report on Moderna

Moderna Stock Down 1.9 %

Shares of MRNA stock opened at $103.61 on Wednesday. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $163.24. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. The company has a 50 day simple moving average of $99.23 and a two-hundred day simple moving average of $93.27.

Moderna (NASDAQ:MRNAGet Free Report) last announced its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. During the same period in the prior year, the company earned $3.61 earnings per share. The firm’s revenue was down 44.9% on a year-over-year basis. On average, analysts expect that Moderna, Inc. will post -7.48 EPS for the current fiscal year.

About Moderna

(Free Report)

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Featured Stories

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.